000142072 001__ 142072
000142072 005__ 20240229105142.0
000142072 0247_ $$2doi$$a10.3390/cancers10110451
000142072 0247_ $$2pmid$$apmid:30453548
000142072 0247_ $$2pmc$$apmc:PMC6265976
000142072 0247_ $$2altmetric$$aaltmetric:51315853
000142072 037__ $$aDKFZ-2018-02302
000142072 041__ $$aeng
000142072 082__ $$a610
000142072 1001_ $$0P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9$$aLarribère, Lionel$$b0$$eFirst author
000142072 245__ $$aTargeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts.
000142072 260__ $$aBasel$$bMDPI$$c2018
000142072 3367_ $$2DRIVER$$aarticle
000142072 3367_ $$2DataCite$$aOutput Types/Journal article
000142072 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550058817_21064
000142072 3367_ $$2BibTeX$$aARTICLE
000142072 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142072 3367_ $$00$$2EndNote$$aJournal Article
000142072 520__ $$aThe mechanisms of adaptive and acquired drug resistance in tumors are not completely understood. So far, gene amplifications or mutations, leading to the reactivation of the MAPK or PI3K pathways have been described. In this study, we used two different methods to generate human melanoblasts: (1) via differentiation from induced pluripotent stem cells (iPSCs) and (2) via dedifferentiation from melanocytes. The melanoblast transcriptomes were then compared to the transcriptome of MAPK inhibitor-resistant melanoma cells. We observed that the expression of genes associated with cell cycle control, DNA damage control, metabolism, and cancer was altered in both melanoblast populations and in both adaptive and acquired resistant melanoma samples, compared to drug-sensitive samples. However, genes involved in antigen presentation and cellular movement were only regulated in the melanoblast populations and in the acquired resistant melanoma samples, compared to the drug-sensitive samples. Moreover, melanocyte-derived melanoblasts and adaptive resistant melanoma samples were characterized by different expression levels of certain transcription factors or genes involved in the CDK5 pathway. In conclusion, we show here that in vitro models of human melanoblasts are very important tools to comprehend the expression profiles of drug-resistant melanoma.
000142072 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142072 588__ $$aDataset connected to CrossRef, PubMed,
000142072 7001_ $$aKuphal, Silke$$b1
000142072 7001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b2
000142072 7001_ $$0P:(DE-He78)20c06d682ef2c877e2610cd1984daea5$$aSachindra, Sachindra$$b3$$eCollaboration Author$$udkfz
000142072 7001_ $$0P:(DE-He78)78e29fad12f1be2fe3d0a8d411f97211$$aHüser, Laura$$b4
000142072 7001_ $$00000-0001-8147-394X$$aBosserhoff, Anja$$b5
000142072 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b6$$eLast author
000142072 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers10110451$$gVol. 10, no. 11, p. 451 -$$n11$$p451$$tCancers$$v10$$x2072-6694$$y2018
000142072 909CO $$ooai:inrepo02.dkfz.de:142072$$pVDB
000142072 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2017
000142072 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142072 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142072 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142072 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142072 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000142072 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000142072 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000142072 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000142072 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142072 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142072 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142072 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142072 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142072 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142072 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2017
000142072 9141_ $$y2018
000142072 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142072 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142072 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)20c06d682ef2c877e2610cd1984daea5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142072 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78e29fad12f1be2fe3d0a8d411f97211$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142072 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000142072 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142072 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x0
000142072 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x1
000142072 980__ $$ajournal
000142072 980__ $$aVDB
000142072 980__ $$aI:(DE-He78)G300-20160331
000142072 980__ $$aI:(DE-He78)E060-20160331
000142072 980__ $$aUNRESTRICTED